Immunotherapy in Lung Cancer Articles

Building on the Momentum of the Durvalumab PACIFIC Trial in Stage III NSCLC
Naomi Fujioka, MD, discusses the clinical implications of the PACIFIC trial in NSCLC treatment and additional questions that are informing planned and ongoing trial designs in stage III disease.
Atezolizumab Monotherapy Improves Survival in Frontline PD-L1-High NSCLC
Single-agent atezolizumab extended overall survival compared with chemotherapy as a frontline treatment for patients with advanced nonsquamous and squamous non–small cell lung cancer and high PD-L1 expression, according to topline findings from the phase III IMpower110 trial.
Immunotherapy Biomarker Hunt Continues in Lung Cancer
Robert A. Kratzke, MD discusses the excitement surrounding immunotherapy and the work being done with biomarkers to assist in making optimal treatment decisions in lung cancer.
Atezolizumab Combo Shows Clinical OS Benefit in PD-L1-High Squamous NSCLC
The addition of atezolizumab (Tecentriq) to carboplatin and nab-paclitaxel (Abraxane) showed a clinical overall survival benefit among a subgroup of patients with advanced squamous non–small cell lung cancer.
Nivolumab Continues to Demonstrate Encouraging OS Rates in NSCLC at 5 Years
Treatment with nivolumab (Opdivo) was associated with a 5-year overall survival rate of 13.4% compared with 2.6% with docetaxel in patients with previously treated non–small cell lung cancer.
Durvalumab Combo Improves Survival in Frontline Small Cell Lung Cancer
Patients with untreated extensive-stage small cell lung cancer had statistically significant improvement in overall survival when the PD-L1 inhibitor durvalumab (Imfinzi) was added to chemotherapy.
Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Approved in Europe for Nonsquamous NSCLC
The European Commission has approved atezolizumab for use in combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with advanced, nonsquamous non–small cell lung cancer.
Atezolizumab Combo Approved in Europe for Small Cell Lung Cancer
The European Commission has approved atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of adult patients with extensive-stage small cell lung cancer, according to Roche (Genentech) the developer of the PD-L1 inhibitor.
Expert Highlights Next Steps With Chemoimmunotherapy in Nonsquamous NSCLC
Manish Patel, DO, discusses advances and remaining questions with chemoimmunotherapy combinations in nonsquamous metastatic non–small cell lung cancer.
FDA Delays Decision on Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC
The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with carboplatin and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer who do not have EGFR or ALK aberrations.
Publication Bottom Border
Border Publication